Canada markets open in 5 hours 9 minutes

Bioasis Technologies Inc. (BTI.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.1600+0.0050 (+3.23%)
At close: 01:53PM EST
Full screen
Previous Close0.1550
Open0.1450
Bid0.1450 x 0
Ask0.1550 x 0
Day's Range0.1450 - 0.1600
52 Week Range0.1200 - 0.3100
Volume20,001
Avg. Volume20,863
Market Cap12.706M
Beta (5Y Monthly)0.24
PE Ratio (TTM)N/A
EPS (TTM)-0.0410
Earnings DateOct 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2022

    NEW HAVEN, Conn., Oct. 28, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and a differentiated, proprietary xB3 ™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, today announced it

  • GlobeNewswire

    Bioasis Technologies Inc. Announces Stock Option Grants

    NEW HAVEN, Conn., Aug. 08, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and a differentiated, proprietary xB3 platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, today announced that

  • GlobeNewswire

    Bioasis Announces Filing of Its First Quarter Financial Statements and MD&A

    NEW HAVEN, Conn., July 29, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (the “BBB”) announced today that it has filed its unaudited quarterly financial statements and management’s discussion and analysis for the period ended May 31, 2022. All are available under the Company’s profile on SEDAR a